everolimus — CareFirst (Caremark)
Progressive and/or symptomatic oncocytic/Hürthle cell carcinoma
Initial criteria
- Used for treatment of specified thyroid carcinomas not amenable to radioactive iodine therapy
Reauthorization criteria
- Continuation may be approved when no unacceptable toxicity or disease progression
Approval duration
12 months